Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T16:26:39.000Z.
Calculation as of: 2026-10-06T16:26:39.000Z.
Quote observation: 2026-10-06T16:25:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: df0d51bc4c7c4fe031789de0e9442acf829cec50a05ec95901a80cda74a8a9f3
PEG RATIO
N/A
Enliven Therapeutics, Inc.
Market Cap
$3.05B
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | $3.05B | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.05B | N/A |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.04B | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.11B | N/A |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.86B | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.81B | N/A |
| AtriCure, Inc. (ATRC)vs › | $2.80B | N/A |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.34B | N/A |
| CareDx, Inc (CDNA)vs › | $3.37B | N/A |
| Precigen, Inc. (PGEN)vs › | $2.71B | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
